USPTO serial 77288446
ENTWRAP
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- MATTHEWS, AMOS
- Law office
- LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ENTWRAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Farah P. Bhatti, Esq.
FARAH P. BHATTI, ESQ. MCDERMOTT WILL & EMERY LLP18191 VON KARMAN AVE STE 500IRVINE, CA 92612-7108UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the treatment of ailments, namely, bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; sanitary preparations for medical purposes; dietetic foods adapted for medical purposes; food for babies; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides; herbicides; medicated films or strips for the treatment of diseases and disorders in humans and animals namely, oral, suppository or topical use, containing an effective dose of one or more drugs/active ingredients, namely, antiinfectives, antibiotics and antivirals; analgesics; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, namely, potassium and calcium blockers, beta-blockers, alpha-blockers and antiarrhythmics; antihypertensives; diuretics and antidiuretics; vasodilators; central nervous system stimulants; vasoconstrictors; cough and cold preparations; decongestants; hormones, namely, estradiol; steroids, corticosieroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; sedatives; tranquilizers; and nicotine; dietetic, mineral or vitamin supplements which consist of pharmaceutical preparations for the treatment of diseases and disorders in humans and animals; medicated breath freshening preparations namely, dissolvable breath strips; fungicides, pesticides or preparations for destroying vermin; dressings for wounds, burns, surgery; oral pharmaceutical preparations in tablet, capsule, film or strip form for the treatment of bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; pharmaceutical preparations, namely, drug delivery systems comprising polymer-based oral tablets, capsule, film or strip form for the continuous release of a wide variety of therapeutic agents; pharmaceutical products, namely, medication for the treatment of bad breath, headaches, body aches, cold and flu symptoms, pain relief, muscular disorders, orthopedic disorders, cancer, cardiovascular disorders, digestive disorders, diabetes, renal disorders, inflammation, auto-immune disorders, gastro-intestinal disorders, hormonal disorders, parasites and skin disorders; medicated lozenges; unit dose capsules sold empty for pharmaceutical use; pharmaceutical capsules filled with liquids or powders for the treatment of animals or humans, namely, oral, suppository or topical use, containing an effective dose of one or more drugs/active ingredients, namely, antiinfectives, antibiotics and antivirals; analgesics; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations, namely, potassium and calcium blockers, beta-blockers, alpha-blockers and antiarrhythmics; antihypertensives; diuretics and antidiuretics; vasodilators; central nervous system stimulants; vasoconstrictors; cough and cold preparations; decongestants; hormones, namely, estradiol; steroids, corticosieroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; sedatives; tranquilizers; and nicotine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 27, 2009 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Apr 27, 2009 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Apr 24, 2009 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Jan 21, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 31, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 14, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 14, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 11, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2008 | ALIE | ASSIGNED TO LIE | — |
| Jun 9, 2008 | PAPER RECEIVED | — | |
| Dec 12, 2007 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2007 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 28, 2007 | NWAP | NEW APPLICATION ENTERED | — |